Prosecution Insights
Prosecution Insights
12 pending office actions • 11 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (42%) |
| §112 only | 4 (33%) |
| No statute on record | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLIN, HEATHER RAQUEL | 2 | 46.5% | +48.9% |
| PADUA, NICO LAUREN | 1 | 9.1% | +15.8% |
| ARNOLD, ERNST V | 1 | 48.0% | +12.9% |
| MELLER, MICHAEL V | 1 | 46.1% | +28.6% |
| PIHONAK, SARAH | 1 | 60.9% | +43.4% |
| NOTTINGHAM, KYLE GREGORY | 1 | 60.8% | +33.8% |
| GONZALEZ, LUISALBERTO | 1 | 61.4% | +47.4% |
| LEE, CHIHYI NMN | 1 | 32.5% | +62.8% |
| STOCKTON, LAURA LYNNE | 1 | 75.0% | +33.8% |
| JANG, JAEICK | 1 | 65.6% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704352 | APPARATUS AND METHOD FOR USING A PRODUCT HAVING AN IN-USE EXPIRY DATE | PADUA, NICO LAUREN | 53d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282096 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | DAHLIN, HEATHER RAQUEL | 16d overdue |
| 18282079 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | DAHLIN, HEATHER RAQUEL | 16d overdue |
| 18283855 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | NOTTINGHAM, KYLE GREGORY | 5d |
| 17801067 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | JANG, JAEICK | 12d |
| 17927762 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | STOCKTON, LAURA LYNNE | 15d |
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 26d |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | ARNOLD, ERNST V | 30d |
| 18551942 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | GONZALEZ, LUISALBERTO | 48d |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 3626 | 1 |
| 1613 | 1 |
| 1655 | 1 |
| 1627 | 1 |
| 1621 | 1 |
| 1624 | 1 |
| 1628 | 1 |
| 1626 | 1 |
| 3785 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704352 | APPARATUS AND METHOD FOR USING A PRODUCT HAVING AN IN-USE EXPIRY DATE | PADUA, NICO LAUREN | 3626 | §103 | Non-Final OA | 53d | Pending | Apr 24, 2024 |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | ARNOLD, ERNST V | 1613 | Other | Non-Final OA | 30d | Pending | Apr 10, 2024 |
| 18576170 | PROCESS FOR THE PREPARATION OF A PULMONARY SURFACTANT | MELLER, MICHAEL V | 1655 | §103 | Non-Final OA | 69d | Pending | Jan 03, 2024 |
| 18283851 | INDOLINE DERIVATIVES AS DDRS INHIBITORS | PIHONAK, SARAH | 1627 | §112 | Final Rejection | — | Pending | Sep 25, 2023 |
| 18283855 | INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS | NOTTINGHAM, KYLE GREGORY | 1621 | §112 | Non-Final OA | 5d | Pending | Sep 25, 2023 |
| 18551942 | 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | 48d | Pending | Sep 22, 2023 |
| 18282096 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | DAHLIN, HEATHER RAQUEL | 1629 | Other | Non-Final OA | 16d overdue | Pending | Sep 14, 2023 |
| 18282079 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | DAHLIN, HEATHER RAQUEL | 1629 | Other | Non-Final OA | 16d overdue | Pending | Sep 14, 2023 |
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | LEE, CHIHYI NMN | 1628 | §103 | Non-Final OA | 26d | Pending | Sep 14, 2023 |
| 17927762 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | STOCKTON, LAURA LYNNE | 1626 | §112 | Final Rejection | 15d | Pending | Nov 25, 2022 |
| 17801067 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | JANG, JAEICK | 3785 | §103 | Final Rejection | 12d | Pending | Aug 19, 2022 |
| 17760354 | PRESSURED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | HAGHIGHATIAN, MINA | 1616 | §103 | Non-Final OA | 26d | Pending | Aug 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial